Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

That includes Perspective Therapeutics (CATX), Indie Semiconductor (INDI), and Travere Therapeutics (TVTX). These three are the top stocks listed on the Analyst Top Stocks tool. CATX could increase by ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...

Armistice Capital lost almost 19% last month, the biggest decline for the hedge fund’s flagship money pool since its launch ...

Ctexli significantly reduced levels of two atypical cholesterol metabolites usually elevated in patients with cerebrotendinous xanthomatosis (CTX) compared to the placebo. Common side effects of ...